Last €5.12 EUR
Change Today -0.03 / -0.58%
Volume 18.6K
EOSI On Other Exchanges
EN Paris
As of 9:57 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

eos imaging sa (EOSI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - €8.29
52 Week Low
01/16/15 - €4.44
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EOS IMAGING SA (EOSI)

Related News

No related news articles were found.

eos imaging sa (EOSI) Related Businessweek News

No Related Businessweek News Found

eos imaging sa (EOSI) Details

EOS Imaging SA designs, develops, and markets patented medical imaging systems used for the treatment of osteo-articular conditions. The company offers a 3D surgical planning service and patient-specific cutting guides for orthopaedic surgeries, as well as sterEOS, an associated review workstation. It also develops and markets patient-specific orthopaedic solutions for hip and knee arthroplasties, which enable surgeons to have cutting guides customized to the anatomy of patient in the operating room. EOS Imaging SA operates in France, EMEA region, North America, and Asia. The company was formerly known as biospace med and changed its name to EOS Imaging SA in 2010. EOS Imaging SA was founded in 1989 and is headquartered in Paris, France.

101 Employees
Last Reported Date: 03/31/14
Founded in 1989

eos imaging sa (EOSI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: €240.1K
Vice President of Marketing
Total Annual Compensation: €112.0K
Compensation as of Fiscal Year 2013.

eos imaging sa (EOSI) Key Developments

EOS Imaging Announces Corporate Agreement with Shriners Hospitals for Children to Facilitate the Acquisition Process of the EOS® System

EOS imaging announced a corporate agreement with Shriners Hospitals for Children to facilitate the acquisition process of the EOS® System throughout the Shriners network of pediatric hospitals in North America. The EOS® System is currently in use at four Shriners hospitals within the network, and the new agreement will streamline the process for all Shriners hospitals to acquire the EOS® System and related service contracts. The agreement between EOS imaging and Shriners Hospitals simplifies the process by which hospitals in the network can acquire the EOS® System through the standardization of activities surrounding corporate approvals, pricing and the establishment of pre-approved terms and agreements. The EOS® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) of radiation reduction by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.

EOS Imaging Receives U.S. Food and Drug Administration Clearance for Micro Dose

EOS imaging announced that the U.S. Food and Drug Administration has cleared the Micro Dose feature for pediatric imaging. Micro Dose represents an important breakthrough for patients with orthopedic conditions requiring frequent imaging exams for the continuous monitoring of disease progression and treatment. Initial results presented at the 2013 French Society of Radiology Annual Meeting (JFR 2013) and during the 2014 Annual Meeting of the Radiological Society of North America (RSNA 2014)2,3 concluded that Micro Dose generates dosage levels equivalent to a week of naturally-occurring background radiation in pediatric patients receiving 2D and 3D follow-up examinations. EOS' continued advancement of low dose radiation imaging addresses an important medical need for pediatric patients that remain particularly sensitive to adverse effects associated with excessive exposure to radiation. Most notably, pediatric patients with scoliosis require frequent imaging sessions to monitor treatment progression, which can increase the risk of radiation-induced cancer later in life4.

EOS Imaging Announces Consolidated Revenue for the Fourth Quarter and Full Year Ended December 31, 2014

EOS imaging announced consolidated revenue for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of EUR 9.09 million against EUR 7.48 million a year ago. For the year, the company reported total revenue of EUR 20.1 million against EUR 15.2 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EOSI:FP €5.12 EUR -0.03

EOSI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EOSI.
View Industry Companies

Industry Analysis


Industry Average

Valuation EOSI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EOS IMAGING SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at